Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 2/20 | 0.59 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.59 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.59 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.59 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.59 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.57 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.53 |
| ▸ | ADRB1 | P08588 | 1/20 | 0.50 |
| ▸ | MIF | P14174 | 1/20 | 0.50 |
| ▸ | HTR2A | P28223 | 1/20 | 0.50 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.50 |
| ▸ | HTR2B | P41595 | 1/20 | 0.50 |
| ▸ | GAA | P10253 | 1/20 | 0.49 |
| ▸ | SLC6A2 | P23975 | 2/20 | 0.47 |
| ▸ | SLC6A4 | P31645 | 2/20 | 0.47 |
| ▸ | SLC6A3 | Q01959 | 2/20 | 0.47 |
| ▸ | CFTR | P13569 | 1/20 | 0.47 |
| ▸ | GOPC | Q9HD26 | 1/20 | 0.47 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.46 |
| ▸ | CYP17A1 | P05093 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30488181 | 1.00 | LMNA (0.59) | LMNAKDM4EADRA2AADRA2CHIF1A | |
| SCHEMBL25269606 | 1.00 | LMNA (0.59) | LMNAKDM4EADRA2AADRA2CHIF1A | |
| SCHEMBL2423599 | 0.84 | SMN1; SMN2 (0.57) | LMNAKDM4ESMN1; SMN2GAASLC6A2 | |
| SCHEMBL4967847 | 0.81 | SMN1; SMN2 (0.53) | LMNAKDM4ESMN1; SMN2GAASLC6A2 | |
| (1S,2R)-Phenylpropanolamine SCHEMBL16992924 | 0.81 | KDM4E (0.77) | LMNAKDM4EADRA2AADRA2CHIF1A | |
| SCHEMBL15675981 | 0.80 | SMN1; SMN2 (0.50) | LMNAKDM4ESMN1; SMN2GAASLC6A2 | |
| SCHEMBL10500850 | 0.80 | SMN1; SMN2 (0.47) | LMNAKDM4ESMN1; SMN2GAASLC6A2 | |
| SCHEMBL1266179 | 0.79 | — | — | |
| SCHEMBL19632996 | 0.79 | — | — | |
| SCHEMBL177932 | 0.79 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2023107630-A2 | AMINO ALCOHOL COMPOUNDS AND USES THEREOF | Kineta, Inc. (US) | 2023-06-15 | — | — | WO | disclosed |
| EP-3199158-B1 | OXAZOLIDIN-2-ONE-PYRIMIDINE DERIVATIVES FOR USE IN THE TREATMENT OF SKIN FIBROSIS, SCLERODERMA, HYPERTROPHIC SCARS OR KELOIDS | NOVARTIS AG (CH) | 2019-04-17 | — | — | EP | disclosed |
| US-10202371-B2 | Oxazolidin-2-one-pyrimidine derivatives and the use thereof as phosphatidylinositol-3-kinase inhibitors | NOVARTIS AG (CH) | 2019-02-12 | — | — | US | disclosed |
| US-10000555-B2 | Monomethylvaline compounds having phenylalanine side-chain modification at the C-terminus | SEATTLE GENETICS, INC. (US) | 2018-06-19 | — | — | US | disclosed |
| EP-3199158-A1 | OXAZOLIDIN-2-ONE-PYRIMIDINE DERIVATIVES FOR USE IN THE TREATMENT OF SKIN FIBROSIS, SCLERODERMA, HYPERTROPHIC SCARS OR KELOIDS | Novartis AG (CH) | 2017-08-02 | — | — | EP | disclosed |
| EP-2922848-B1 | OXAZOLIDIN-2-ONE-PYRIMIDINE DERIVATIVES | NOVARTIS AG (CH) | 2017-06-28 | — | — | EP | disclosed |
| US-20160168145-A1 | OXAZOLIDIN-2-ONE-PYRIMIDINE DERIVATIVES AND THE USE THEREOF AS PHOSPHATIDYLINOSITOL-3-KINASE INHIBITORS | NOVARTIS AG (CH) | 2016-06-16 | — | — | US | disclosed |
| US-9296733-B2 | Oxazolidin-2-one-pyrimidine derivative and use thereof for the treatment of conditions, diseases and disorders dependent upon PI3 kinases | NOVARTIS AG (CH) | 2016-03-29 | — | — | US | disclosed |
| EP-2922848-A1 | OXAZOLIDIN-2-ONE-PYRIMIDINE DERIVATIVES | Novartis AG (CH) | 2015-09-30 | — | — | EP | disclosed |
| US-20140135330-A1 | Oxazolidin-2-one-Pyrimidine Derivatives | NOVARTIS AG (CH) | 2014-05-15 | — | — | US | disclosed |
| WO-2014072956-A1 | OXAZOLIDIN-2-ONE-PYRIMIDINE DERIVATIVES | NOVARTIS AG (CH) | 2014-05-15 | — | — | WO | disclosed |
| US-20130123465-A1 | MONOMETHYLVALINE COMPOUNDS HAVING PHENYLALANINE SIDE-CHAIN MODIFICATIONS AT THE C-TERMINUS | SEATTLE GENETICS, INC. (US) | 2013-05-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130123465-A1 | MONOMETHYLVALINE COMPOUNDS HAVING PHENYLALANINE SIDE-CHAIN MODIFICATIONS AT THE C-TERMINUS | MMAB, PTMS, DNPEP | LMNA 578/4885KDM4E 648/4885ADRA2A 4552/4885 |
| US-10202371-B2 | Oxazolidin-2-one-pyrimidine derivatives and the use thereof as phosphatidylinositol-3-kinase inhibitors | PIK3CA, PIK3CD, PIK3CB | LMNA 3688/4885KDM4E 2992/4885ADRA2A 4079/4885 |
| US-20140135330-A1 | Oxazolidin-2-one-Pyrimidine Derivatives | PIK3CA, PIK3CD, PIK3CB | LMNA 3852/4885KDM4E 3202/4885ADRA2A 3922/4885 |
| US-20160168145-A1 | OXAZOLIDIN-2-ONE-PYRIMIDINE DERIVATIVES AND THE USE THEREOF AS PHOSPHATIDYLINOSITOL-3-KINASE INHIBITORS | PIK3CA, PIK3CD, PIK3CB | LMNA 3688/4885KDM4E 2992/4885ADRA2A 4079/4885 |
| US-10000555-B2 | Monomethylvaline compounds having phenylalanine side-chain modification at the C-terminus | PTMS, MMAB, DNPEP | LMNA 572/4885KDM4E 608/4885ADRA2A 4560/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.